FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 338:1397-1404 May 14, 1998 Number 20 Next

	Full Text PDF Editorial by Utiger, R. D. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Sildenafil is a potent inhibitor of cyclic guanosine monophosphate in the corpus cavernosum and therefore increases the penile response to sexual stimulation. We evaluated the efficacy and safety of sildenafil, administered as needed in two sequential double-blind studies of men with erectile dysfunction of organic, psychogenic, or mixed causes.

Methods In a 24-week dose–response study, 532 men were treated with oral sildenafil (25, 50, or 100 mg) or placebo. In a 12-week, flexible dose-escalation study, 329 different men were treated with sildenafil or placebo, with dose escalation to 100 mg based on efficacy and tolerance. After this dose-escalation study, 225 of the 329 men entered a 32-week, open-label extension study. We assessed efficacy according to the International Index of Erectile Function, a patient log, and a global-efficacy question.

Results In the dose–response study, increasing doses of sildenafil were associated with improved erectile function (P values for increases in scores for questions about achieving and maintaining erections were <0.001). For the men receiving 100 mg of sildenafil, the mean score for the question about achieving erections was 100 percent higher after treatment than at base line (4.0 vs. 2.0 of a possible score of 5). In the last four weeks of treatment in the dose-escalation study, 69 percent of all attempts at sexual intercourse were successful for the men receiving sildenafil, as compared with 22 percent for those receiving placebo (P<0.001). The mean numbers of successful attempts per month were 5.9 for the men receiving sildenafil and 1.5 for those receiving placebo (P<0.001). Headache, flushing, and dyspepsia were the most common adverse effects in the dose-escalation study, occurring in 6 percent to 18 percent of the men. Ninety-two percent of the men completed the 32-week extension study.

Conclusions Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.

Source Information

From the Department of Urology, Boston University Medical Center, Boston (I.G.); the Department of Urology, University of California, San Francisco (T.F.L.); the Department of Urology, University of Southern California, Los Angeles, and the Male Clinic, Santa Monica, Calif. (H.P.-N.); the Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, N.J. (R.C.R.); the Department of Urology, University of Virginia, Charlottesville (W.D.S.); and Pfizer Central Research, Groton, Conn. (P.A.W.).

Address reprint requests to Dr. Goldstein at the Department of Urology, Boston University Medical Center, 720 Harrison Ave., P (606), Boston, MA 02118.

Full Text of this Article

Related Letters:

Sildenafil in the Treatment of Erectile Dysfunction
Shah P.K., Schwartz I., McCarthy D., Saldana M. J., Villaran C., Alhalel B., Little W. N., Park G. T., Patton H. M., Meikle A. W., Arver S., Marshall K. G., Budenholzer B., Goldstein I., Rosen R. C., Steers W. D., The Sildenafil Study Group
Extract | Full Text  
N Engl J Med 1998; 339:699-702, Sep 3, 1998. Correspondence

This article has been cited by other articles:

• Menniti, F. S., Ren, J., Coskran, T. M., Liu, J., Morton, D., Sietsma, D. K., Som, A., Stephenson, D. T., Tate, B. A., Finklestein, S. P. (2009). Phosphodiesterase 5A Inhibitors Improve Functional Recovery after Stroke in Rats: Optimized Dosing Regimen with Implications for Mechanism. J. Pharmacol. Exp. Ther. 331: 842-850 [Abstract] [Full Text]  
• Qaseem, A., Snow, V., Denberg, T. D., Casey, D. E. Jr., Forciea, M. A., Owens, D. K., Shekelle, P., for the Clinical Efficacy Assessment Subcommittee, (2009). Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians. ANN INTERN MED 151: 639-649 [Abstract] [Full Text]  
• Tsertsvadze, A., Fink, H. A., Yazdi, F., MacDonald, R., Bella, A. J., Ansari, M. T., Garritty, C., Soares-Weiser, K., Daniel, R., Sampson, M., Fox, S., Moher, D., Wilt, T. J. (2009). Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis. ANN INTERN MED 151: 650-661 [Abstract] [Full Text]  
• Tsertsvadze, A., Fink, H. A., Yazdi, F., MacDonald, R., Bella, A. J., Ansari, M. T., Garritty, C., Soares-Weiser, K., Daniel, R., Sampson, M., Fox, S., Moher, D., Wilt, T. J. (2009). Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis. ANN INTERN MED 0: 0000605-200911030-00150v1-E-150 [Abstract] [Full Text]  
• Qaseem, A., Snow, V., Denberg, T. D., Casey, D. E. Jr., Forciea, M. A., Owens, D. K., Shekelle, P., for the Clinical Efficacy Assessment Subcommittee, (2009). Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians. ANN INTERN MED 0: 0000605-200911030-00151v1-E-151 [Abstract] [Full Text]  
• Wylie, K, Malik, F (2009). Review of drug treatment for female sexual dysfunction. Int J STD AIDS 20: 671-674 [Abstract] [Full Text]  
• Olanow, C. W., Stern, M. B., Sethi, K. (2009). The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72: S1-S136 [Abstract] [Full Text]  
• Rich, S. (2009). The Effects of Vasodilators in Pulmonary Hypertension: Pulmonary Vascular or Peripheral Vascular?. Circ Heart Fail 2: 145-150 [Full Text]  
• Foster, R, Mears, A, Goldmeier, D (2009). A literature review and case reports series on the use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction. Int J STD AIDS 20: 152-157 [Abstract] [Full Text]  
• Toda, N., Ayajiki, K., Okamura, T. (2009). Cerebral Blood Flow Regulation by Nitric Oxide: Recent Advances. Pharmacol. Rev. 61: 62-97 [Abstract] [Full Text]  
• GIRARDIN, F., BERNEY, P., SCHULZ, P. (2009). An Early Report on the Role of Nitrates in Erectile Dysfunction. Am. J. Psychiatry 166: 115-115 [Full Text]  
• Guazzi, M. (2008). Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure. Circ Heart Fail 1: 272-280 [Full Text]  
• Nurnberg, H. G., Hensley, P. L., Heiman, J. R., Croft, H. A., Debattista, C., Paine, S. (2008). Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction: A Randomized Controlled Trial. JAMA 300: 395-404 [Abstract] [Full Text]  
• Lubamba, B., Lecourt, H., Lebacq, J., Lebecque, P., De Jonge, H., Wallemacq, P., Leal, T. (2008). Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 177: 506-515 [Abstract] [Full Text]  
• Guillaume, M., Lonsdale, F., Darstein, C., Jimenez, M. C., Mitchell, M. I. (2007). Hemodynamic Interaction Between a Daily Dosed Phosphodiesterase 5 Inhibitor, Tadalafil, and the {alpha}-Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle-Aged Healthy Male Subjects. J Clin Pharmacol 47: 1303-1310 [Abstract] [Full Text]  
• Mandras, S. A., Uber, P. A., Mehra, M. R. (2007). Sexual Activity and Chronic Heart Failure. Mayo Clin Proc. 82: 1203-1210 [Abstract] [Full Text]  
• Kass, D. A. (2007). Hypertrophied Right Hearts Get Two for the Price of One: Can Inhibiting Phosphodiesterase Type 5 Also Inhibit Phosphodiesterase Type 3?. Circulation 116: 233-235 [Full Text]  
• Raina, R., Pahlajani, G., Agarwal, A., Zippe, C. D. (2007). Treatment of Erectile Dysfunction: Update. Am J Mens Health 1: 126-138 [Abstract]  
• Roizenblatt, S., Guilleminault, C., Poyares, D., Cintra, F., Kauati, A., Tufik, S. (2006). A Double-blind, Placebo-Controlled, Crossover Study of Sildenafil in Obstructive Sleep Apnea.. Arch Intern Med 166: 1763-1767 [Abstract] [Full Text]  
• Baquero, H., Soliz, A., Neira, F., Venegas, M. E., Sola, A. (2006). Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study. Pediatrics 117: 1077-1083 [Abstract] [Full Text]  
• Gopalakrishnan, R., Jacob, K.S., Kuruvilla, A., Vasantharaj, B., John, J. K. (2006). Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial. Am. J. Psychiatry 163: 494-499 [Abstract] [Full Text]  
• Rochira, V., Balestrieri, A., Madeo, B., Granata, A. R. M., Carani, C. (2006). Sildenafil Improves Sleep-Related Erections in Hypogonadal Men: Evidence From a Randomized, Placebo-Controlled, Crossover Study of a Synergic Role for Both Testosterone and Sildenafil on Penile Erections. J Androl 27: 165-175 [Abstract] [Full Text]  
• Beckman, T. J., Abu-Lebdeh, H. S., Mynderse, L. A. (2006). Evaluation and Medical Management of Erectile Dysfunction. Mayo Clin Proc. 81: 385-390 [Abstract] [Full Text]  
• Caglayan, E., Huntgeburth, M., Karasch, T., Weihrauch, J., Hunzelmann, N., Krieg, T., Erdmann, E., Rosenkranz, S. (2006). Phosphodiesterase Type 5 Inhibition Is a Novel Therapeutic Option in Raynaud Disease. Arch Intern Med 166: 231-233 [Abstract] [Full Text]  
• Pitari, G. M., Baksh, R. I., Harris, D. M., Li, P., Kazerounian, S., Waldman, S. A. (2005). Interruption of Homologous Desensitization in Cyclic Guanosine 3',5'-Monophosphate Signaling Restores Colon Cancer Cytostasis by Bacterial Enterotoxins. Cancer Res. 65: 11129-11135 [Abstract] [Full Text]  
• Fries, R., Shariat, K., von Wilmowsky, H., Bohm, M. (2005). Sildenafil in the Treatment of Raynaud's Phenomenon Resistant to Vasodilatory Therapy. Circulation 112: 2980-2985 [Abstract] [Full Text]  
• Raina, R., Nandipati, K. C., Agarwal, A., Mansour, D., Kaelber, D. C., Zippe, C. D. (2005). Combination Therapy: Medicated Urethral System for Erection Enhances Sexual Satisfaction in Sildenafil Citrate Failure Following Nerve-Sparing Radical Prostatectomy. J Androl 26: 757-760 [Abstract] [Full Text]  
• Borlaug, B. A., Melenovsky, V., Marhin, T., Fitzgerald, P., Kass, D. A. (2005). Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans. Circulation 112: 2642-2649 [Abstract] [Full Text]  
• Thethi, T. K., Asafu-Adjaye, N. O., Fonseca, V. A. (2005). Erectile Dysfunction. Clin. Diabetes 23: 105-113 [Abstract] [Full Text]  
• Setter, S. M, Iltz, J. L, Fincham, J. E, Campbell, R K., Baker, D. E (2005). Phosphodiesterase 5 Inhibitors for Erectile Dysfunction. The Annals of Pharmacotherapy 39: 1286-1295 [Abstract] [Full Text]  
• Lee, E. S. (2005). Sexual Dysfunction After Conventional And Endovascular AAA Repair: Results of the DREAM Trial. PERSPECT VASC SURG ENDOVASC THER 17: 177-1-179 [Abstract]  
• Fowler, C J, Miller, J R, Sharief, M K, Hussain, I F, Stecher, V J, Sweeney, M (2005). A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76: 700-705 [Abstract] [Full Text]  
• Wareing, M., Myers, J. E., O'Hara, M., Baker, P. N. (2005). Sildenafil Citrate (Viagra) Enhances Vasodilatation in Fetal Growth Restriction. J. Clin. Endocrinol. Metab. 90: 2550-2555 [Abstract] [Full Text]  
• Brown, J. S., Wessells, H., Chancellor, M. B., Howards, S. S., Stamm, W. E., Stapleton, A. E., Steers, W. D., Van Den Eeden, S. K., McVary, K. T. (2005). Urologic Complications of Diabetes. Diabetes Care 28: 177-185 [Full Text]  
• Kloner, R. A. (2004). Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction. Circulation 110: 3149-3155 [Full Text]  
• Hood, S., Kirby, M. (2004). Review: PDE-5 inhibitors -- a summary. British Journal of Diabetes & Vascular Disease 4: 383-386 [Abstract]  
• Mikhail, N. (2004). Efficacy and Safety of Sildenafil in Patients With Congestive Heart Failure. Arch Intern Med 164: 2067-2068 [Full Text]  
• Lau, D. H W, Mumtaz, F. H, Thompson, C. S, Mikhailidis, D. P (2004). Erectile dysfunction: a need for greater awareness. The Journal of the Royal Society for the Promotion of Health 124: 214-216 [Abstract]  
• Morgentaler, A. (2004). A 66-Year-Old Man With Sexual Dysfunction. JAMA 291: 2994-3003 [Full Text]  
• Webster, L. J., Michelakis, E. D., Davis, T., Archer, S. L. (2004). Use of Sildenafil for Safe Improvement of Erectile Function and Quality of Life in Men With New York Heart Association Classes II and III Congestive Heart Failure: A Prospective, Placebo-Controlled, Double-blind Crossover Trial. Arch Intern Med 164: 514-520 [Abstract] [Full Text]  
• Karkos, C. D., Wood, A., Bruce, I. A., Karkos, P. D., Baguneid, M. S., Lambert, M. E. (2004). Erectile Dysfunction After Open Versus Angioplasty Aortoiliac Procedures: A Questionnaire Survey. VASC ENDOVASCULAR SURG 38: 157-165 [Abstract]  
• Leuchte, H. H., Schwaiblmair, M., Baumgartner, R. A., Neurohr, C. F., Kolbe, T., Behr, J. (2004). Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension. Chest 125: 580-586 [Abstract] [Full Text]  
• Fox, K. M., Thadani, U., Ma, P. T.S., Nash, S. D., Keating, Z., Czorniak, M. A., Gillies, H., Keltai, M., on behalf of the CAESAR I investigators, (2003). Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 24: 2206-2212 [Abstract] [Full Text]  
• Kloner, R. A., Hutter, A. M., Emmick, J. T., Mitchell, M. I., Denne, J., Jackson, G. (2003). Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 42: 1855-1860 [Abstract] [Full Text]  
• Vlachopoulos, C., Hirata, K., O'Rourke, M. F (2003). Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 8: 243-248 [Abstract]  
• Polak, K., Wimpissinger, B., Berisha, F., Georgopoulos, M., Schmetterer, L. (2003). Effects of Sildenafil on Retinal Blood Flow and Flicker-Induced Retinal Vasodilatation in Healthy Subjects. IOVS 44: 4872-4876 [Abstract] [Full Text]  
• Thompson, C. A., Shanafelt, T. D., Loprinzi, C. L. (2003). Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation. The Oncologist 8: 474-487 [Abstract] [Full Text]  
• Reffelmann, T., Kloner, R. A. (2003). Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease. Circulation 108: 239-244 [Full Text]  
• van Lankveld, J. J.D.M., van den Hout, M. A., Spigt, M. G., van Koeveringe, G. A. (2003). Cognitive Changes Predict Continued Recovery of Erectile Functioning Versus Relapse After Discontinuation of Sildenafil Treatment for Male Erectile Dysfunction. Psychosom. Med. 65: 709-718 [Abstract] [Full Text]  
• Liu, P. Y., Death, A. K., Handelsman, D. J. (2003). Androgens and Cardiovascular Disease. Endocr. Rev. 24: 313-340 [Abstract] [Full Text]  
• Toda, N., Okamura, T. (2003). The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels. Pharmacol. Rev. 55: 271-324 [Abstract] [Full Text]  
• Penson, D. F., Latini, D. M., Lubeck, D. P., Wallace, K. L., Henning, J. M., Lue, T. F. (2003). Do Impotent Men With Diabetes Have More Severe Erectile Dysfunction and Worse Quality of Life Than the General Population of Impotent Patients?: Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 26: 1093-1099 [Abstract] [Full Text]  
• Stuckey, B. G.A., Jadzinsky, M. N., Murphy, L. J., Montorsi, F., Kadioglu, A., Fraige, F., Manzano, P., Deerochanawong, C. (2003). Sildenafil Citrate for Treatment of Erectile Dysfunction in Men With Type 1 Diabetes: Results of a randomized controlled trial. Diabetes Care 26: 279-284 [Abstract] [Full Text]  
• Nurnberg, H. G., Hensley, P. L., Gelenberg, A. J., Fava, M., Lauriello, J., Paine, S. (2003). Treatment of Antidepressant-Associated Sexual Dysfunction With Sildenafil: A Randomized Controlled Trial. JAMA 289: 56-64 [Abstract] [Full Text]  
• Seftel, A. D. (2002). Challenges in Oral Therapy for Erectile Dysfunction. J Androl 23: 729-736 [Full Text]  
• Schalcher, C., Schad, K., Brunner-La Rocca, H. P., Schindler, R., Oechslin, E., Scharf, C., Suetsch, G., Bertel, O., Kiowski, W. (2002). Interaction of Sildenafil With cAMP-Mediated Vasodilation In Vivo. Hypertension 40: 763-767 [Abstract] [Full Text]  
• Burnett, A. L. (2002). Nitric Oxide Regulation of Penile Erection: Biology and Therapeutic Implications. J Androl 23: S20-S26 [Full Text]  
• Bocchi, E. A., Guimaraes, G., Mocelin, A., Bacal, F., Bellotti, G., Ramires, J. F. (2002). Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectile Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction. Circulation 106: 1097-1103 [Abstract] [Full Text]  
• Maas, R., Schwedhelm, E., Albsmeier, J., Boger, R. H (2002). The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 7: 213-225 [Abstract]  
• Bloomgarden, Z. T. (2002). American Association of Clinical Endocrinologists Meeting, May 2002. Diabetes Care 25: 1464-1471 [Full Text]  
• Chiang, C.-E., Luk, H.-N., Wang, T.-M., Ding, P. Y.-A. (2002). Effects of sildenafil on cardiac repolarization. Cardiovasc Res 55: 290-299 [Abstract] [Full Text]  
• Ali, W., Besarani, D., Kirby, R. (2002). Review: Modern treatment of erectile dysfunction. British Journal of Diabetes & Vascular Disease 2: 255-261 [Abstract]  
• Jackson, G. (2002). Cardiovascular safety in erectile dysfunction treatment. British Journal of Diabetes & Vascular Disease 2: 301-304 [Abstract]  
• Hackett, G. (2002). Schedule 11 -- impact on treating erectile dysfunction. British Journal of Diabetes & Vascular Disease 2: 315-318 [Abstract]  
• Rochira, V., Granata, A. R. M., Balestrieri, A., Madeo, B., Carani, C. (2002). Effects of Sildenafil on Nocturnal Penile Tumescence and Rigidity in Normal Men: Randomized, Placebo-Controlled, Crossover Study. J Androl 23: 566-571 [Abstract] [Full Text]  
• Fink, H. A., Mac Donald, R., Rutks, I. R., Nelson, D. B., Wilt, T. J. (2002). Sildenafil for Male Erectile Dysfunction: A Systematic Review and Meta-analysis. Arch Intern Med 162: 1349-1360 [Abstract] [Full Text]  
• Eherer, A J, Schwetz, I, Hammer, H F, Petnehazy, T, Scheidl, S J, Weber, K, Krejs, G J (2002). Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 50: 758-764 [Abstract] [Full Text]  
• Benevento, B. T, Sipski, M. L (2002). Neurogenic Bladder, Neurogenic Bowel, and Sexual Dysfunction in People With Spinal Cord Injury. ptjournal 82: 601-612 [Abstract] [Full Text]  
• Hoeper, M. M., Galie, N., Simonneau, G., Rubin, L. J. (2002). New Treatments for Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 165: 1209-1216 [Full Text]  
• Dey, J., Shepherd, M. D. (2002). Evaluation and Treatment of Erectile Dysfunction in Men With Diabetes Mellitus. Mayo Clin Proc. 77: 276-282 [Abstract]  
• Arruda-Olson, A. M., Mahoney, D. W., Nehra, A., Leckel, M., Pellikka, P. A. (2002). Cardiovascular Effects of Sildenafil During Exercise in Men With Known or Probable Coronary Artery Disease: A Randomized Crossover Trial. JAMA 287: 719-725 [Abstract] [Full Text]  
• Fishman, J. R. (2002). Sex, Drugs, and Clinical Research. Mol. Interv. 2: 12-16 [Full Text]  
• Pache, M., Meyer, P., Prunte, C., Orgul, S., Nuttli, I., Flammer, J. (2002). Sildenafil induces retinal vasodilatation in healthy subjects. Br J Ophthalmol 86: 156-158 [Abstract] [Full Text]  
• Nurnberg, H. G., Gelenberg, A., Hargreave, T. B., Harrison, W. M., Siegel, R. L., Smith, M. D. (2001). Efficacy of Sildenafil Citrate for the Treatment of Erectile Dysfunction in Men Taking Serotonin Reuptake Inhibitors. Am. J. Psychiatry 158: 1926-1928 [Abstract] [Full Text]  
• Seidman, S. N., Roose, S. P., Menza, M. A., Shabsigh, R., Rosen, R. C. (2001). Treatment of Erectile Dysfunction in Men With Depressive Symptoms: Results of a Placebo-Controlled Trial With Sildenafil Citrate. Am. J. Psychiatry 158: 1623-1630 [Abstract] [Full Text]  
• Turk, S., Karalezli, G., Tonbul, H. Z., Yildiz, M., Altintepe, L., Yildiz, A., Yeksan, M. (2001). Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 16: 1818-1822 [Abstract] [Full Text]  
• Charan, N. B. (2001). Does Sildenafil Also Improve Breathing?. Chest 120: 305-306 [Abstract] [Full Text]  
• Giuliano, F., Allard, J., Compagnie, S., Alexandre, L., Droupy, S., Bernabe, J. (2001). Vaginal physiological changes in a model of sexual arousal in anesthetized rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281: R140-R149 [Abstract] [Full Text]  
• Sato, Y., Zhao, W., Christ, G. J. (2001). Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281: R269-R278 [Abstract] [Full Text]  
• Olanow, C. W., Watts, R. L., Koller, W. C. (2001). An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment. Neurology 56: S1-S88 [Full Text]  
• Cohan, P., Korenman, S. G. (2001). Erectile Dysfunction. J. Clin. Endocrinol. Metab. 86: 2391-2394 [Full Text]  
• Moreland, R. B., Hsieh, G., Nakane, M., Brioni, J. D. (2001). The Biochemical and Neurologic Basis for the Treatment of Male Erectile Dysfunction. J. Pharmacol. Exp. Ther. 296: 225-234 [Full Text]  
• EARDLEY, I., MORGAN, R., DINSMORE, W., YATES, P., BOOLELL, M. (2001). Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. Br. J. Psychiatry 178: 325-330 [Abstract] [Full Text]  
• Behn, D., Potter, M. J. (2001). Sildenafil-Mediated Reduction in Retinal Function in Heterozygous Mice Lacking the {{gamma}}-Subunit of Phosphodiesterase. IOVS 42: 523-527 [Abstract] [Full Text]  
• Wagner, G., Montorsi, F., Auerbach, S., Collins, M. (2001). Sildenafil Citrate (VIAGRA(R)) Improves Erectile Function in Elderly Patients With Erectile Dysfunction: A Subgroup Analysis. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56: 113M-119 [Abstract] [Full Text]  
• Phillips, B. G., Kato, M., Pesek, C. A., Winnicki, M., Narkiewicz, K., Davison, D., Somers, V. K. (2000). Sympathetic Activation by Sildenafil. Circulation 102: 3068-3073 [Abstract] [Full Text]  
• Harrold, L. R., Gurwitz, J. H., Field, T. S., Andrade, S. E., Fish, L. S., Jarry, P. D., Yood, R. A. (2000). The Diffusion of a Novel Therapy Into Clinical Practice: The Case of Sildenafil. Arch Intern Med 160: 3401-3405 [Abstract] [Full Text]  
• Ishikura, F., Beppu, S., Hamada, T., Khandheria, B. K., Seward, J. B., Nehra, A. (2000). Effects of Sildenafil Citrate (Viagra) Combined With Nitrate on the Heart. Circulation 102: 2516-2521 [Abstract] [Full Text]  
• Meston, C. M., Frohlich, P. F. (2000). The Neurobiology of Sexual Function. Arch Gen Psychiatry 57: 1012-1030 [Abstract] [Full Text]  
• Ayub, W., Fletcher, S. (2000). End-stage renal disease and erectile dysfunction. Is there any hope?. Nephrol Dial Transplant 15: 1525-1528 [Full Text]  
• Medina, P., Segarra, G., Martinez-Leon, J. B., Vila, J. M., Aldasoro, M., Otero, E., Lluch, S. (2000). Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann. Thorac. Surg. 70: 1327-1331 [Abstract] [Full Text]  
• Michelakis, E., Tymchak, W., Archer, S. (2000). Sildenafil: from the bench to the bedside. CMAJ 163: 1171-1175 [Abstract] [Full Text]  
• Araujo, A. B., Johannes, C. B., Feldman, H. A., Derby, C. A., McKinlay, J. B. (2000). Relation between Psychosocial Risk Factors and Incident Erectile Dysfunction: Prospective Results from the Massachusetts Male Aging Study. Am J Epidemiol 152: 533-541 [Abstract] [Full Text]  
• Katz, S. D., Balidemaj, K., Homma, S., Wu, H., Wang, J., Maybaum, S. (2000). Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36: 845-851 [Abstract] [Full Text]  
• Noto, T., Inoue, H., Ikeo, T., Kikkawa, K. (2000). Potentiation of Penile Tumescence by T-1032, a New Potent and Specific Phosphodiesterase Type V Inhibitor, in Dogs. J. Pharmacol. Exp. Ther. 294: 870-875 [Abstract] [Full Text]  
• Ralph, D., McNicholas, T. (2000). UK management guidelines for erectile dysfunction. BMJ 321: 499-503 [Full Text]  
• Geelen, P., Drolet, B., Rail, J., Berube, J., Daleau, P., Rousseau, G., Cardinal, R., O'Hara, G. E., Turgeon, J. (2000). Sildenafil (Viagra) Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current. Circulation 102: 275-277 [Abstract] [Full Text]  
• Webb, D. J., Muirhead, G. J., Wulff, M., Sutton, J. A., Levi, R., Dinsmore, W. W. (2000). Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 36: 25-31 [Abstract] [Full Text]  
• Smith, K. J., Roberts, M. S. (2000). The Cost-Effectiveness of Sildenafil. ANN INTERN MED 132: 933-937 [Abstract] [Full Text]